Predicting how well children and young adults with lymphoma respond to treatment

Lead researcher - Dr Amos Burke, Addenbrooke’s Hospital, Cambridge
Cancer type - Burkitt lymphoma
Determination of the prognostic significance of MDD and MRD in paediatric Burkitt lymphoma/leukaemia
Amount awarded: £128,600
Award start date: 01 Apr 2014
Award duration: 5 years (60 months)

Dr Burke and his team at Addenbrooke’s Hospital, Cambridge are looking at lymphoma samples taken from the Inter-B-NHL Ritux 2010 clinical trial. The trial has now shown that adding a drug called rituximab to existing treatments improves survival for  children and young adults with advanced stage aggressive lymphomas, such as Burkitt lymphoma or diffuse large B cell lymphoma.

Dr Burke will seek to predict how well the treatment works by using tests that can detect lymphoma cells in the bone marrow and blood, and will use them before and after treatment to track response.

This research could lead to the development of a test that can predict how well a person will respond to their treatment.